WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007002373) USE OF MUTANT HERPES SIMPLEX VIRUS-2 FOR CANCER THERAPY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/002373    International Application No.:    PCT/US2006/024440
Publication Date: 04.01.2007 International Filing Date: 23.06.2006
IPC:
A61K 35/76 (2006.01), C12N 7/01 (2006.01)
Applicants: BAYLOR COLLEGE OF MEDICINE [US/US]; One Baylor Plaza, BCM210-600D, Houston, Texas 77030 (US) (For All Designated States Except US).
ZHANG, Xiaoliu [CN/US]; (US) (For US Only).
FU, Xinping [CN/US]; (US) (For US Only)
Inventors: ZHANG, Xiaoliu; (US).
FU, Xinping; (US)
Agent: WEBER, Kenneth A.; Townsend and Townsend and Crew LLP 2 Embarcadero Center, 8th Floor San Francisco, California 94111 (US)
Priority Data:
60/693,157 23.06.2005 US
Title (EN) USE OF MUTANT HERPES SIMPLEX VIRUS-2 FOR CANCER THERAPY
(FR) UTILISATION DE L'HERPES SIMPLEX VIRUS TYPE 2 MUTANT DANS LE TRAITEMENT DU CANCER
Abstract: front page image
(EN)The present invention is directed to the composition and use of a modified Herpes Simplex Virus Type 2 (HSV-2) as a medicament in the treatment of cancer. The modified HSV-2 has fusogenic activity, and comprises a modified/mutated ICP10 polynucleotide encoding a polypeptide having ribonucleotide reductase activity and lacking protein kinase activity.
(FR)L'invention concerne la composition et l'utilisation d'un herpès simplex virus type 2 modifié (HSV-2) en tant que médicament dans le traitement du cancer. Le HSV-2 modifié possède une activité fusogène, et comprend un polynucléotide ICP10 modifié/muté codant un polypeptide possédant l'activité de la ribonucléotide réductase et dépourvu de l'activité de la protéine kinase.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)